FiercePharmaOriginal article
{"a":[{"_":"AZ, Daiichi's Enhertu scores long-awaited NICE blessing in HER2-low breast cancer","$":{"href":"/pharma/az-daiichis-enhertu-wins-long-awaited-nice-blessing","hreflang":"en"}}]}
RegulatoryapprovedEnhertuPositive
AI Analysis
Summary
NICE has approved Enhertu (AstraZeneca/Daiichi Sankyo) as cost effective for NHS use in HER2-low advanced breast cancer, reversing a 2024 rejection.
Outcome Details
NICE deemed Enhertu cost effective for NHS use in HER2-low advanced breast cancer
Importance:7/10
Sentiment:
0.80
NICE approvalantibody drug conjugatebreast cancerHER2-lowNHS reimbursement
Read the original article
Published by FiercePharma on September 16, 2026 3:14 PM